Impact of temporalis muscle thickness in elderly patients with newly diagnosed glioblastoma treated with radio or radio-chemotherapy

[1]  R. Stupp,et al.  Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials , 2021, Clinical Cancer Research.

[2]  T. Tominaga,et al.  Standard values for temporal muscle thickness in the Japanese population who undergo brain check-up by magnetic resonance imaging , 2021, Surgical neurology international.

[3]  G. Reifenberger,et al.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.

[4]  M. Scorsetti,et al.  Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis , 2020, European Radiology.

[5]  Y. Zha,et al.  Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma , 2020, Frontiers in Neurology.

[6]  H. Yeşil Çınkır,et al.  Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme? , 2020, Asia-Pacific journal of clinical oncology.

[7]  M. Hwang,et al.  Temporalis muscle width as a measure of sarcopenia correlates with overall survival in patients with newly diagnosed glioblastoma , 2019, Journal of Radiation Oncology.

[8]  M. J. van den Bent,et al.  Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. , 2019, Neuro-oncology.

[9]  H. Lee,et al.  Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy , 2019, Nutrition and cancer.

[10]  G. Minniti,et al.  Glioblastoma in Elderly Patients: Current Management and Future Perspectives , 2019, Cancers.

[11]  P. Costelli,et al.  The Skeletal Muscle as an Active Player Against Cancer Cachexia , 2019, Front. Physiol..

[12]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.

[13]  S. Piccirillo,et al.  Basic and Translational Advances in Glioblastoma , 2018, BioMed Research International.

[14]  A. della Puppa,et al.  Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology) , 2015, Journal of Neuro-Oncology.

[15]  V. Zagonel,et al.  Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). , 2015 .

[16]  F. Pasqualetti,et al.  Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. , 2014, Anticancer research.

[17]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Cairncross,et al.  A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. , 1994, International journal of radiation oncology, biology, physics.